Clinical Trial Update: Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1

View source ↗

Summary

This is a Non-Significant Risk (NSR) clinical trial evaluating [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on the RefleXion X1 for prostate cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ILLUCCIX (Kit for the preparation of gallium Ga-68 gozetotide injection)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Prostate Cancer | Status: RECRUITING